The 11th International Symposium on Myelodysplastic Syndromes
Webcasted Presentations

Search’n Build™

Opening Ceremony7 presentations / courses
Welcome and Introduction
by David Bowen
2011-05-18 7 minutes  
Welcome and Introduction
by Stephen Nimer
2011-05-18 9 minutes    
Patient: Doctor Relationship - FAQ
by David Steensma
2011-05-18 24 minutes    
Patient: Doctor Relationship - Perceptions
by Mikkael Sekeres
2011-05-18 21 minutes    
Patient Support Groups
by David Hall
2011-05-18 14 minutes  
Patient Support Groups
by Patrick Festy
2011-05-18 14 minutes    
History of Medicine in Edinburgh
by Iain Milne
2011-05-18 23 minutes  
 
Plenary 1: Diagnosis I - Morphology2 presentations / courses
Introductory Debate: Morphology is Dead, Long Live Morphology
by Ulrich Germing
2011-05-19 10 minutes    
Introductory Debate: Morphology is Dead, Long Live Morphology
by Ghulam Mufti
2011-05-19 9 minutes  
Standardization of flow cytometric analysis in myelodysplastic syndromes
by Matteo Giovanni Della Porta
2011-05-19 10 minutes  
Diagnostic and Prognostic Value of MFC
by Arjan Van de Loosdrecht
2011-05-19 14 minutes  
Cytogenetics - for how much longer?
by Brigitte Schlegerberger
2011-05-19 14 minutes  
Molecular Analysis as a Diagnostic Tool
by Timothy Graubert
2011-05-19 13 minutes    
Plenary 3: Prognosis3 presentations / courses
Recent Advances in Cytogenetic Risk Scoring in MDS
by Detlef Haase
2011-05-19 11 minutes    
New Prognostic Scores and Q&A
by Mario Cazzola
2011-05-19 14 minutes    
The added value of quality-of-life and other patient-reported outcomes in cli...
by Fabio Efficace
2011-05-19 10 minutes  
 
Cellular identity, molecular determinants and clinical surveillance of MDS st...
by Sten Eirik Jacobsen
2011-05-19 19 minutes    
Hematopoietic stem cells and leukemia in the niche and Q&A
by Toshio Suda
2011-05-19 14 minutes    
Acute myeloid leukemia and hematopoietic lineage commitment and Q&A
by Claus Nerlov
2011-05-19 17 minutes  
 
Plenary 5: Pathogenesis 15 presentations / courses
Molecular pathogenesis of the 5q- syndrome and Q&A
by Andrea Pellagatti
2011-05-19 11 minutes    
Prognostic impact of TP53 mutations in MDS with del(5q) and Q&A
by Martin Jadersten
2011-05-19 18 minutes    
5Q and Q&A
by Benjamin L. Ebert
2011-05-19 16 minutes    
Mouse Models of MDS and Q&A
by Sten Eirik Jacobsen
2011-05-19 10 minutes    
Ectopic innate immune signaling in marrow cells results in an MDS phenotype
by Aly Karsan
2011-05-19 11 minutes  
 
Plenary 6: Pathogenesis II2 presentations / courses
Myeloid-derived suppressor cells (MDSC) are effectors of bone marrow suppress...
by Sheng Wei
2011-05-19 13 minutes  
Vaccine Therapy for Myeloid Malignancy and Q&A
by Katayoun Rezvani
2011-05-19 15 minutes    
Plenary 7: MDS / MPS4 presentations / courses
New Mutations in MDS and Q&A
by Joop Jansen
2011-05-20 14 minutes    
New mutations in MDS/MPN and Q&A
by Nick Cross
2011-05-20 12 minutes  
Gene deletions and mutations in chronic myelomonocytic leukaemia and Q&A
by Daniel Birnbaum
2011-05-20 10 minutes    
Juvenile myelomonocytic leukemia: How many entities? and Q&A
by C. Niemeyer
2011-05-20 11 minutes    
Plenary 8: Bone Marrow Failure2 presentations / courses
Refractory Cytopenia in Childhood and Q&A
by Marcin Wlodarski
2011-05-20 11 minutes  
PNH: New Insights and Q&A
by Peter Hillmen
2011-05-20 19 minutes  
Plenary 9: Management of Low Risk MDS7 presentations / courses
Management of 1000 patients with low- and intermediate-1 risk myelodysplastic...
by Louise de Swart
2011-05-20 12 minutes  
Iron Overload / Toxicity; Mechanisms and Measurement and Q&A
by John B. Porter
2011-05-20 13 minutes  
Debate: Iron chelation therapy, as recommended in National MDS Management Gui...
by Dr. David Steensma and Prof. Norbert Gattermann
2011-05-20 31 minutes    
Thrombomimetic agents in myelodysplastic syndromes and Q&A
by Honar Cherif
2011-05-20 10 minutes    
Guidelines for immunosuppression in MDS
by Pearlie Epling-Burnette
2011-05-20 16 minutes    
Debate: Lenalidomide is the standard of care for the management of isolated d...
by Martin Jadersten
2011-05-20 9 minutes  
Debate: Lenalidomide is the standard of care for the management of isolated d...
by Pierre Fenaux
2011-05-20 10 minutes  
 
Introduction to epigenetic regulation and Q&A
by Kirsten Groenbaek
2011-05-20 23 minutes  
The Role of Hypomethylating Agents in High-Risk MDS and Q&A
by lionel Adès
2011-05-20 24 minutes  
Optimising combination strategies and Q&A
by Mikkael Sekeres
2011-05-20 24 minutes    
 
Plenary 11: Transplantation in MDS5 presentations / courses
Conditioning regimen for allogeneic stem cell transplantation in MDS and Q&A
by Nicolaus Kröger
2011-05-21 18 minutes    
Allogeneic stem cell transplantation from alternative stem cell sources in my...
by G.F. Sanz
2011-05-21 14 minutes  
Optimising pre and post transplant management and Q&A
by Uwe Platzbecker
2011-05-21 17 minutes  
Debate: Transfusion versus Transplant (Including Indications and Timing)
by Corey S. Cutler
2011-05-21 10 minutes    
Debate: Transfusion versus Transplant (Including Indications and Timing)
by Ghulam Mufti
2011-05-21 8 minutes  
 
Nucleoside Analogues and Q&A
by Guillermo Garcia Manero
2011-05-21 18 minutes    
International research activity in MDS - Novel Therapeutics and Q&A
by A. List
2011-05-21 22 minutes  
The identification of novel somatic mutations in MDS by whole exome sequencing
by Elli Papaemmanuil
2011-05-21 9 minutes    
Next-generation sequencing technology combined with multiplexed barcoded samp...
by Yasunobu Nagata
2011-05-21 10 minutes  
A retrospective time-dependent comparative analysis of the impact of lenalido...
by Joaquin Sanchez
2011-05-21 7 minutes  
ASXL1 is frequently mutated and associated with a negative prognosis in MDS
by Felicitas Thol
2011-05-21 7 minutes